RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.
6 Apr, 2022 | 10:51h | UTCCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Related:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.